	porpolaity.	
It is made available	under a CC-BY	4.0 International license

1	Investigation of locomotive syndrome improvement by
2	total hip arthroplasty in patients with hip osteoarthritis: a
3	before-after comparative study focusing on 25-question
4	geriatric locomotive function scale
5	
6	Short title:
7	Investigation of locomotive syndrome improvement by THA in hip osteoarthritis
8	individuals
9	
10	Shigeaki Miyazaki <sup>1</sup> *, Kurumi Tsuruta <sup>2</sup> , Saori Yoshinaga <sup>3</sup> , Yoshinori Fujii <sup>4</sup> , Amy
11	Hombu <sup>5</sup> , Taro Funamoto <sup>6</sup> , Takero Sakamoto <sup>6</sup> , Takuya Tajima <sup>6</sup> , Yoshihiro Nakamura <sup>6</sup> ,
12	Hideki Arakawa <sup>1</sup> , Jun Nakatake <sup>1</sup> , Etsuo Chosa <sup>7</sup>
13	
14	<sup>1</sup> Rehabilitation Unit, University of Miyazaki Hospital, 5200 Kihara Kiyotake Miyazaki,
15	Miyazaki 889-1692, Japan
16	<sup>2</sup> Department of Nursing, Faculty of Human Health Sciences, Shunan University, 843-4-
17	2 Gakuendai, Shunan, Yamaguchi 745-8566, Japan
18	<sup>3</sup> School of Nursing, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake
19	Miyazaki, Miyazaki 889-1692, Japan
20	<sup>4</sup> Department of Mathematics Education, Faculty of Education, University of Miyazaki,
21	1-1 Gakuen Kibanadai-nishi, Miyazaki, Miyazaki 889-2192, Japan
22	<sup>5</sup> Center for Language and Cultural Studies, Lecturer, University of Miyazaki, 1-1 Gakuen

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 Kibanadai-nishi, Miyazaki, Miyazaki 889-2192, Japan
- <sup>6</sup>Department of Orthopaedic Surgery, Faculty of Medicine, University of Miyazaki, 5200
- 25 Kihara Kiyotake Miyazaki, Miyazaki 889-1692, Japan
- <sup>7</sup>Community Medical Center, University of Miyazaki Hospital, 1-6-2 Minamihara Tano
- 27 Miyazaki, Miyazaki 889-1704, Japan

- 30 \* Corresponding author
- 31 E-mail: 03-5-23@med.miyazaki-u.ac.jp (SM)

# 47 Abstract

#### 48 Background

The 25-Question Geriatric Locomotive Function Scale (GLFS-25) is one of the tests used to assess the risk of locomotive syndrome (LS). It is a comprehensive tool to measure LS improvement after total hip arthroplasty (THA) and provides beneficial information for rehabilitation after THA. This study aims to investigate the effectiveness of LS improvement three months after THA in patients who underwent THA for hip osteoarthritis (OA) by using the total clinical decision limits (CDL) 3-stage scale to identify specific trends in LS improvement based on the GLFS-25.

#### 56 Methods

57 The participants of this study were 273 patients who underwent primary THA for hip OA.

58 LS was evaluated using the stand-up test, two-step test, and GLFS-25 before receiving

59 THA and three months after THA.

#### 60 **Results**

The total CDL was improved by THA in 132 patients (improvement rate: 48.4%). There were 15 questions out of 25 in the GLFS-25 showed improvements in more than 60% of the patients. The question Q13, "To what extent has it been difficult to walk briskly?" revealed the highest improvement rate, followed by Q12, "To what extent has it been difficult to go up and down stairs?", and Q3, "Did you have any pain (including numbness) in your lower limbs?".

#### 67 Conclusions

At three months after THA, approximately half of the patients showed improvement in
LS. Furthermore, improvement in locomotion movements was identified as the most
significant area of progress among motor functions.

71

## 72 Introduction

The aging population is a significant issue around the world. The number of people aged 60 and over reached 1 billion in 2019. This number is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. This increase will continue to accelerate in the coming decades, especially in developing countries [1]. The number of elderly people requiring nursing care is expanding due to motor dysfunction [2]. Ensuring the elderly can maintain a good quality of life (QOL) can benefit both individuals and society.

79 Locomotive syndrome (LS) was introduced by the Japanese Orthopedic 80 Association (JOA) in 2007 to evaluate motor functions due to locomotive organ 81 impairment [3]. LS leads to the risk of requiring future long-term health care [4-6]. In 82 2013, JOA developed the LS risk tests consisting of a stand-up test, two-step test, and 25-83 Question Geriatric Locomotive Function Scale (GLFS-25) to assess LS [7]. Additionally, 84 in 2015, JOA implemented clinical decision limits (CDL) as criteria for determining the 85 risks of LS [8]. The CDL classifies the LS into stage 1 or stage 2 [7]; in 2020, stage 3 was 86 added, making CDL a three-stage evaluation instrument [9,10].

Total hip arthroplasty (THA) is a surgical treatment to regain hip joint function, relieve pain, and improve the limitations of activities of daily living (ADL) in patients with hip osteoarthritis (OA). THA has shown effectiveness in enhancing QOL, including walking function [11], sports activities [12], and cardiopulmonary function [13], which

91 leads to early reintegration into society. Larsen et al. [14] reported that early perioperative 92 care and rehabilitation can significantly shorten hospital stay and improve QOL three 93 months after THA. Furthermore, Miyazaki et al. [9] reported that the improvement rate 94 in total CDL three months after THA was 46.7%, indicating that patients could recover 95 to independent walking three months after THA. The demonstration of the effectiveness 96 in improving LS based on the short-term results due to THA is clinically significant.

97 The GLFS-25, one of the LS risk tests, was developed as a screening instrument 98 for elderly patients with motor dysfunctions [15, 16]. A comprehensive consideration of 99 LS improvement after THA using the GLFS-25 provides beneficial information for 100 implementing after THA rehabilitation. Regarding the effect of THA on improving the 101 GLFS-25, previous studies reported that 90% of patients with severe hip joint disorders 102 required nursing care before THA. This percentage dropped to 30% three months after 103 THA [17]. Unfortunately, up to date, no short-term results at three months after THA in 104 hip OA patients have been reported concerning the effect of LS improvement using the 105 total CDL stages 1 to 3. Furthermore, there is no study to examine the trend or degree of 106 progress for each question in the GLFS-25. This study aims to investigate the 107 effectiveness of LS improvement at three months after THA in patients who underwent 108 THA for hip OA by using the total CDL 3-stage scale to identify specific trends in LS 109 improvement based on the GLFS-25.

110

### **Materials and Methods**

#### 112 Study design and ethical statement

113 This before-after comparative study was approved by the Research Ethics Committee of 114 the University of Miyazaki, School of Medicine (Approval No. O-0783). It was carried 115 out in compliance with the Ethical Guidelines for Medical and Biological Research 116 Involving Human Subjects at the Department of Rehabilitation Medicine, University of 117 Miyazaki Affiliated Hospital. The participants of this study were patients who underwent 118 primary THA for hip OA between October 2018 and May 2024. Approval for this study 119 was obtained from the Research Ethics Committee in September 2020. Therefore, data 120 collected before obtaining approval from the Research Ethics Committee were 121 categorized as a retrospective study, while data collected after obtaining approval were 122 categorized as a prospective study. All data used in the retrospective study were fully 123 anonymized prior to access. As it was not feasible to contact participants in the 124 retrospective study and because the information was initially collected for clinical 125 purposes, the opt-out method was applied in accordance with ethical guidelines. 126 Information regarding the conduct of the research including the objectives was disclosed 127 and the research participants were provided an opportunity to refuse inclusion in the 128 research.

129

### 130 **Patient selection**

The participants of this study were patients who underwent primary THA for hip OA. The target patients agreed to participate in both before THA and three months after THA evaluations. Patients with femoral head necrosis, trauma, rheumatoid arthritis, infection, and patients with incomplete outcome measure data sets were excluded from the study. As a result of careful selection and rigorous screening, 273 patients were included in this

study (Fig 1). The breakdown of the total CDL stages was: 0 patients of stage 0, 1 patients
of stage 1, 27 patients of stage 2, and 245 patients of stage 3. The cohort in this study
included patients with polyarticular disease and those who have undergone arthroplasty
in other joints.

140

#### 141 Fig 1. Flowchart of the included patients.

The participants of this study were patients who underwent primary THA for hip OA between October 2018 and May 2024. Patients with femoral head necrosis, trauma, rheumatoid arthritis, infection, and patients with incomplete outcome measure data sets were excluded from the study.

146

All cases in this study underwent THA using the anterior minimally invasive surgery (AMIS) approach or transgluteal approach performed by experienced orthopedic surgeons at the hospital of the authors' affiliated institution. Rehabilitation after THA started the day after THA for three months. Patients received one-on-one rehabilitation twice a day for 60 to 80 minutes during hospitalization. Outpatients received one-on-one rehabilitation for 20 to 40 minutes two to three times a week.

153

#### 154 **Outcome measures**

155 The three LS risk tests proposed by JOA, the stand-up test, two-step test, GLFS-25, and 156 total CDL stage, were adopted as outcome measures in this before-after comparative 157 study [7]. For evaluation, the CDL and total CDL results of each test were classified into

stages 0 to 3. All measures were performed both before and three months after THA. Datawere collected as previously described in Miyazaki et al. [10].

160 1. For the stand-up test, following the JOA guidelines, four different stool heights 161 were used: 40 cm, 30 cm, 20 cm, and 10 cm. First, a patient was asked to stand up from 162 the sitting position starting at the highest stool of 40 cm. After being able to stand up with 163 both legs, the next step was to stand up with one leg. After that, the test continues using 164 stools at different heights. The evaluation employed a 9-point scale [7]: 0 points (unable 165 to stand); 1, 2, 3, and 4 points (stand on both legs from heights of 40 cm, 30 cm, 20 cm, 166 and 10 cm, respectively); 5, 6, 7, and 8 points (stand on one leg from heights of 40 cm, 167 30 cm, 20 cm, and 10 cm, respectively). Scores <2, <3, and <5 were classified as CDL 168 stages 3, 2, and 1, respectively. The instructions to quantify motion were given. (1) Fold 169 arms in front of the chest at a sitting position. (2) Place feet shoulder-width apart. (3) 170 Position lower legs at an angle of approximately 70° to the floor. (4) Stand up without 171 gaining momentum. (5) Maintain the standing posture for 3 seconds.

172 2. The two-step test is used to evaluate stride length. A patient was asked to take 173 two steps with the longest possible stride, and the stride length of these two steps was 174 measured. The test score was calculated by dividing the stride length of these two steps 175 by the patient's height. Scores <0.9,  $\ge 0.9$  to <1.1, and  $\ge 1.1$  to <1.3 were classified into 176 CDL stages 3, 2, and 1, respectively. The instructions to quantify motion were given. (1) Align toes at the starting line with a stationary standing position. (2) Take two of the 177 178 longest possible steps forward, then align toes together in a stationary standing position. 179 (3) If the subject loses balance, start over. (4) Measure the stride length of the two steps. 180 (5) Perform two times and adopt the better score.

1813. The GLFS-25 [15] is a self-administered assessment of 25 questions. This test182consists of four questions measuring physical pain, 16 questions measuring ADL, three183questions measuring social functions, and two questions measuring mental health in the184past month before the test. These 25 questions are rated on a 5-point scale ranging from185no functional impairment (0 points) to severe functional impairment (4 points), and a total186score is calculated (minimum 0 points, maximum 100 points). Scores  $\geq 24$ ,  $\geq 16$  to < 24,187and  $\geq 7$  to <16 were classified into CDL stages 3, 2, and 1, respectively.

4. The total CDL was determined based on the results of the stand-up test, two-step
test, and GLFS-25. As a result, the most advanced stage of mobility impairment can be
determined based on the CDL stages.

191

### 192 Statistical Analysis

193 The following statistical analyses were performed.

Evaluation of LS improvement: The Wilcoxon signed-rank test was used to
 compare the distribution of the CDL stages for the three LS risk tests and the total CDL
 stages.

197 2. Changes in each of the LS test scores and each of the GLFS-25 questions before198 THA and three months after THA were examined using a Paired t-test.

This is an observational study with a longitudinal design. At the time of applying for ethical approval, we could not predict how many cases we would have over the 6-year period. As a result, we had 273 participants eligible for this study, all of whom underwent primary THA at the hospital during the study period, excluding those who did not meet the patient selection criteria. All statistical analyses were performed using IBM SPSS

204 27.0 (IBM Corp., Released 2020. Armonk, NY, USA). The statistical significance was

```
205 set at p < .05.
```

206

# 207 **Results**

Table 1 shows the age, sex, height, weight, and BMI. The participants were 273 patients comprising 52 males and 221 females, and the mean age was 67.4 years (standard deviation SD: 9.3 years). The mean BMI was 24.4 kg/m<sup>2</sup> (standard deviation SD: 3.8

211 kg/m<sup>2</sup>).

212

213

Table 1. Characteristics of the patients.		
Characteristic	Total (n = 273)	
Age (years)	$67.4 \pm 9.3$	
Sex: male/female	52 / 221	
Height (cm)	$154.3 \pm 7.6$	
Weight (kg)	$58.4 \pm 11.0$	
Body mass index (BMI) (kg/m <sup>2</sup> )	$24.4 \pm 3.8$	
BMI, body mass index.		
Age, height, weight, and BMI values	are means $\pm$ standard dev	iation.

215

214

Table 2 shows the participants' medical information. Among the participants in this study, 53 patients (19.4%) had primary hip OA, and 220 (80.6%) patients had secondary hip OA. Regarding THA, 217 (79.5%) patients were unilateral, and 56 (20.5%) patients were bilateral. Regarding the surgical procedure, 156 (57.1%) patients had the AMIS approach, and 117 (42.9%) patients had the transgluteal approach. Regarding the stage

- on the non-operated side, in the order of stages 0 to 4, the details were 39 (14.3%), 52
- 222 (19.0%), 39 (14.3%), 35 (12.8%), and 45 (16.5%) patients, respectively, and 63 (23.1%)
- 223 were after THA. On the operated side, in the order of stages 0 to 4, the details were 0
- 224 (0%), 0 (0%), 0 (0%), 33 (12.1%), and 240 (87.9%) patients, respectively.

Table 2. Patients' medical informa	tion.		n = 273
Item	Category	Frequency	%
Diagnosis	Primary hip osteoarthritis	53	19.4
	Secondary hip osteoarthritis	220	80.6
THA	Unilateral	217	79.5
	Bilateral	56	20.5
Surgical procedure	AMIS approach	156	57.1
	Transgluteal approach	117	42.9
JOA staging (non-operated side)	Stage 0	39	14.3
	Stage 1	52	19.0
	Stage 2	39	14.3
	Stage 3	35	12.8
	Stage 4	45	16.5
	After THA	63	23.1
JOA staging (operated side)	Stage 0	0	0
	Stage 1	0	0
	Stage 2	0	0
	Stage 3	33	12.1
	Stage 4	240	87.9

- 226 Table 3 shows the distributions of the CDL stages for the three LS tests and the
- 227 total CDL stages for all participants. There was a significant change in the percentage of
- 228 participants in each CDL stage from before THA to three months after THA (p < .001).
- 229 At three months, the percentage of participants with total CDL stage 3 decreased, while
- 230 the percentage of participants with total CDL stages 2, 1, and 0 increased. The same trend
- 231 was detected in the distribution for each of the three tests in LS.

		Stage 0		e 0 Stage 1		Stage 2		Stage 3		Wilcoxon signed-rank test
		N	%	Ν	%	N	%	N	%	<i>p</i> -value
Stand-up test	Before THA	7	2.6	84	30.8	82	30.0	100	36.6	< 0.001***
	3 months after THA	16	5.9	98	35.9	92	33.7	67	24.5	< 0.001***
Two-step test	Before THA	3	1.1	36	13.2	101	37.0	133	48.7	< 0.001***
	3 months after THA	14	5.1	80	29.3	115	42.1	64	23.4	< 0.001***
GLFS-25	Before THA	0	0.0	5	1.8	34	12.5	234	85.7	< 0.001***
	3 months after THA	32	11.7	91	33.3	65	23.8	85	31.1	< 0.001***
Total CDL stage	Before THA	0	0.0	1	0.4	27	9.9	245	89.7	< 0.001***
	3 months after THA	2	0.7	51	18.7	93	34.1	127	46.5	< 0.001***

- Table 4 shows the changes observed in total CDL due to THA. THA improved the
- total CDL in 132 patients with an improvement rate of 48.4%. Before THA, 27 patients
- were in LS stage 2, of which seven (25.9%) improved to LS stage 1, and one (3.7%) to
- LS stage 0 after THA. Similarly, among 246 patients who were LS stage 3 before THA,
- 237 80 (32.5%) improved to LS stage 2, 43 (17.5%) to LS stage 1, and one (0.4%) to LS stage
- 238 0.

3 months	Stage 0		Stage	Stage 1		Stage 2		Stage 3		Total	
Before THA	after THA	N	%	Ν	%	N	%	N	%	N	%
Stage 2		1	3.7	7	25.9	13	48.2	6	22.2	27	100
Stage 3		1	0.4	43	17.5	80	32.5	122	49.6	246	100
Гotal		2	0.7	50	18.3	93	34.1	128	46.9	273	100

- 241 Table 5 shows the significant differences (p < .001) observed in the scores for all
- 242 cases in the three LS risk tests (stand-up test, two-step test, and GLFS-25) between before
- 243 THA and three months after THA. The scores of the stand-up test and the two-step test
- 244 were significantly higher at three months after THA. The GLFS-25 score was
- 245 significantly lower at three months after THA.

	Before THA (mean ± SD)	3 months after THA (mean ± SD)	Paired <i>t</i> -test <i>p</i> -value	
Stand-up test	$2.06 \pm 1.21$	$2.36 \pm 1.17$	< 0.001***	
Two-step test	$0.88\pm0.22$	$1.01 \pm 0.20$	< 0.001***	
GLFS-25	$40.9 \pm 16.0$	$19.3 \pm 12.4$	< 0.001***	
LS, locomotive syndrome;	THA, total hip arthroplasty; SD	, standard deviation;		
GLFS-25, 25-Question Ger	atric Locomotive Function Sca	le.		
Significantly different: ***	v < .001			

248	The differences in the GLFS-25 scores before THA and three months after THA are
249	shown using a scatter plot (Fig 2). There is a negative correlation between the GLFS-25
250	score before THA and the change in the GLFS-25 score (three months after THA minus
251	before THA), and the change in the GLFS-25 score increased in proportion to the GLFS-
252	25 score before THA. As a result of regression analysis, the regression coefficient was -
253	0.723 and the coefficient of determination ( $\mathbb{R}^2$ ) was 0.498 ( $p < .001$ ).
254	
255	Figure 2. Scatter plot graph of GLFS-25 score.
256	The scatter plot shows the correlation between the GLFS-25 score before THA and the
257	change in the GLFS-25 score (three months after THA minus before THA).
258	
259	Table 6 shows the average score difference between before and three months after
260	THA for each GLFS-25 question and the percentage of patients who improved in three
261	months after THA compared to the before THA evaluation. For all questions, there was
262	a significant difference between the scores before THA and three months after THA; in
263	other words, the scores three months after THA were lower than before THA.
264	Furthermore, the percentage of patients who improved was over 60% for 15 out of the 25
265	questions, and the question with the highest percentage of patients who improved was
266	Q13 (80.2%). This was followed by Q12 (76.9%), Q3 (76.2%), Q4 (74.7%), Q7 (72.5%),
267	and Q21 (70.7%). On the other hand, the question with the lowest improvement rate was
268	Q8 (24.5%).

items	Before THA (mean ± SD)	3 months after THA (mean ± SD)	Difference (mean ± SE)	Improvement rate (%)
Q1. Did you have any pain (including numbness) in your neck or upper limbs?	$0.78\pm0.92$	$0.66 \pm 0.82$	$0.12 \pm 0.06*$	30.8
Q2. Did you have any pain in your back, lower back or buttocks?	$1.32 \pm 1.08$	$0.90\pm0.92$	0.42 ± 0.07 ***	46.2
Q3. Did you have any pain (including numbness) in your lower limbs?	$2.23 \pm 1.06$	$0.89 \pm 0.83$	1.33 ± 0.08 ***	76.2
Q4. To what extent has it been painful to move your body in daily life?	$2.09 \pm 0.92$	$0.82 \pm 0.78$	1.27 ± 0.07 ***	74.7
Q5. To what extent has it been difficult to get up from a bed or lie down?	$1.29 \pm 0.99$	$0.43 \pm 0.65$	0.85 ± 0.07 ***	60.4
Q6. To what extent has it been difficult to stand up from a chair?	$1.35 \pm 0.99$	$0.44 \pm 0.62$	0.91 ± 0.06 ***	60.4
Q7. To what extent has it been difficult to walk inside the house?	$1.36 \pm 0.95$	$0.34 \pm 0.58$	1.03 ± 0.06 ***	72.5
Q8. To what extent has it been difficult to put on and take off shirts?	$0.41 \pm 0.77$	$0.14 \pm 0.39$	0.27 ± 0.05 ***	24.5
Q9. To what extent has it been difficult to put on and take off trousers and pants?	$1.80 \pm 0.96$	$0.76 \pm 0.65$	1.04 ± 0.06 ***	68.5
Q10. To what extent has it been difficult to use the toilet?	$0.87 \pm 0.90$	$0.21 \pm 0.44$	0.66 ± 0.06 ***	50.5
211. To what extent has it been difficult to wash your body in the bath?	$1.11 \pm 0.97$	$0.47 \pm 0.62$	0.65 ± 0.06 ***	49.1
Q12. To what extent has it been difficult to go up and down stairs?	$2.37\pm0.99$	$1.06 \pm 0.84$	1.31 ± 0.07 ***	76.9
Q13. To what extent has it been difficult to walk briskly?	$2.62 \pm 1.02$	$1.16 \pm 0.89$	1.46 ± 0.07 ***	80.2
214. To what extent has it been difficult to keep yourself neat?	$1.01 \pm 0.94$	$0.34 \pm 0.57$	0.67 ± 0.06 ***	50.9
Q15. How far can you keep walking without rest?	2.67 ± 1.12	$1.52 \pm 1.16$	1.14 ± 0.08 ***	69.2
216. To what extent has it been difficult to go out to visit neighbors?	$1.44 \pm 1.09$	$0.40 \pm 0.66$	1.04 ± 0.07 ***	67.8
217. To what extent has it been difficult to carry objects weighing approximately 2 kilograms	$1.73 \pm 1.23$	$0.82 \pm 0.93$	0.90 ± 0.08 ***	60.8
218. To what extent has it been difficult to go out using public transportation?	$2.00 \pm 1.26$	$0.86 \pm 0.98$	1.14 ± 0.08 ***	66.7

				1
Q19. To what extent have simple tasks and housework been difficult?	$1.13 \pm 0.95$	$0.39 \pm 0.63$	0.74 ± 0.06 ***	57.9
Q20. To what extent have load-bearing tasks and housework been difficult?	$1.81 \pm 1.17$	$0.92\pm0.89$	0.89 ± 0.07 ***	60.1
Q21. To what extent has it been difficult to perform sports activity?	$2.93 \pm 1.03$	$1.70 \pm 1.16$	1.23 ± 0.08 ***	70.7
Q22. Have you been restricted from meeting your friends?	$1.36 \pm 1.32$	$1.00 \pm 1.18$	0.36 ± 0.08 ***	38.1
Q23. Have you been restricted from joining social activities ?	$2.29 \pm 1.46$	$1.66 \pm 1.48$	$0.63 \pm 0.10$ ***	48.0
Q24. Have you ever felt anxious about falls in your house?	$1.30 \pm 1.05$	$0.76\pm0.77$	0.54 ± 0.07 ***	44.3
Q25. Have you ever felt anxious about being unable to walk in the future?	$1.68 \pm 1.16$	$0.64 \pm 0.76$	1.04 ± 0.08 ***	64.8
Improvement rate is the comparison of before THA and 3 months after	er THA			
GLFS-25, 25-Question Geriatric Locomotive Function Scale; THA, to	tal hip arthroplasty; SD,	standard deviation; SI	E, standard error.	
Paired <i>t</i> -test, Significantly different: $*p < .05$ , $***p < .001$				

# 271 **Discussion**

272 This study evaluated patients with hip OA who underwent primary THA for each CDL 273 stage and total CDL stage of LS risk tests before and three months after THA to assess 274 the effectiveness of THA. In addition, the specific trends of LS improvement in motor 275 function based on the GLFS-25 were examined. To the best of our knowledge, there have 276 been no short-term evaluations at three months after THA in hip OA patients, including 277 evaluation by total CDL stage 1 to 3 or evaluation of LS improvement after THA based 278 on the GLFS-25. Therefore, this study is the first to clarify the therapeutic effects of THA 279 on LS and the motor function questions related to LS improvement from the GLFS-25, 280 focusing on three months after THA. The most important findings from this study were 281 that total CDL improved in 48.4% of patients three months after THA; 15 out of 25 (60%) 282 GLFS-25 questions revealed an improvement rate of over 60% in patients.

283 THA has been a well-received surgery that rebuilds hip joint function and improves 284 pain and restrictions in ADL due to locomotive organ impairment. Previous studies 285 reported implant survival rates exceeding 20 years after surgery [18, 19]. Consequently, 286 it is rather crucial to clarify the improvement rate of total CDL after THA. In a cohort study examining the effects of THA in hip OA patients, the improvement rate in total 287 288 CDL stage 1 and stage 2 evaluation was 57% at six months and 65% at one year after 289 THA [20]. In a 2-year post-THA cohort study, the improvement rate in total CDL stage 290 1 and stage 2 evaluation was 56.8% [21]. In addition, a cohort study examining the short-291 term effects of THA reported that the improvement rate when evaluating total CDL stage 292 3 alone was 46.7% at three months after THA [9]. Our study is the first to evaluate total 293 CDL in all stages, 1 to 3. Although it is not realistic to conduct a simple comparison with

294 previous reports due to the time frame differences, our total CDL improvement rate three 295 months after THA was 48.4% which was in line with other studies. Regarding the 296 improvement change by total CDL stage, the improvement rate from stage 3 to stage 2, 297 1, or 0 was 50.4%, and some patients did show an improvement from stage 3 to 0. The 298 improvement rate from stage 2 to 1 or 0 was 29.6%. This is to say that THA due to hip 299 OA can improve LS within a short period of time after surgery.

300 In the present study, we investigated the specific trends of improvement by THA 301 using the GLFS-25. The results showed that there was a negative correlation between the 302 GLFS-25 score pre-THA and the change in the GLFS-25 score (three months after THA 303 minus before THA). The changes seen in the scores toward the negative direction (-) 304 indicate improvement in most patients. Furthermore, the higher the GLFS-25 score before 305 THA and the higher the difficulty in ADL, the greater the improvement in score. 306 Regarding the improvement effect of THA on the GLFS-25, Maezawa et al. [17] reported 307 that the GLFS-25 improved from 55.4 points before THA to 19.1 points three months 308 after THA. Our present study showed that the CDL stage in the GLFS-25 significantly 309 decreased from 234 (85.7%) patients with CDL stage 3 before THA to 85 (31.1%) 310 patients three months after THA. A significant improvement in the GLFS-25 score was 311 also observed by 21.6 points (40.9 points before THA minus 19.3 points three months 312 after THA).

The GLFS-25 assesses the following four categories: pain-related (Q1 to 4), ADLrelated (Q5 to 20), social function-related (Q21 to 23), and mental health-related (Q24, 25) [15]. Both Q3 and Q4 correspond to hip joint pain-related. The score for both Q3 and Q4 was improved from two points (moderate pain) or higher before THA to less than one point (little pain) three months after THA, and the improvement rate revealed was over

318 70% in patients. Consequently, many improvement cases in hip joint pain were observed three months after THA. Regarding ADL-related, the improvement rate was 55% and 319 320 higher in 12 questions except Q8, Q10, Q11, and Q14. These four questions mainly 321 evaluate upper limb functions that have no substantial influence on THA. The scores 322 before THA were 0.41 (not difficult) to 1.11 (slightly difficult), which were low to begin 323 with, so the percentage of patients who improved their scores tended to be low. All other 324 questions in this category evaluate locomotion movements. There were many 325 improvements observed due to THA and rehabilitation. Regarding questions related to 326 mental health, both Q24 (anxiety about falling) and Q25 (anxiety about difficulty in 327 walking) were less than one point (slightly anxious) after three months of THA, indicating 328 significant improvement. Q21 (sports activities) is one of the questions regarding social 329 functions. It indicates the most active mobility of ADL, which is the most difficult part 330 for hip OA patients. The score for Q21 was 2.93, at the level of "quite difficult" before 331 THA, the highest of all questions. Three months after THA, the score decreased to 1.70, 332 indicating a high improvement rate of 70.7%. The above results suggest that pain 333 reduction and improved mobility have alleviated the anxiety of falling and difficulty in 334 walking, which has led to improvement in sports activities.

Seichi et al. [15] reported that the questions of the GLFS-25 reflect the existence of multidimensional and interrelated structures in clusters. According to their study, based on seven questions (Q12, 13, 15, 16, 17, 19, 20), one cluster was formed consisting of questions associated with physical functions of ADL (walking and housework activities). This cluster presents significant relationships with other clusters and is demonstrated to be a key domain. The results from our present study revealed that the improvement rate for all seven questions was 55% and higher. Among them, the improvement rate for

questions related to walking and stair climbing (Q12, 13, 15, 16, 17) ranged from 60.8%
to 80.2%. For questions related to household activities (Q19, 20), the improvement rate
remained at 57.9% and 60.1%. These results indicate that, among motor functions,
locomotion movements showed improvements ahead of housework activities three
months after THA.

The present study has two limitations that need to be considered. Firstly, both unilateral and bilateral hip OA were included in the study. Secondly, both AMIS and transgluteal surgical procedures were included. Therefore, in our further research, it is necessary to investigate whether these factors may have an impact on the improvement effect of LS.

352

### 353 **Conclusions**

354 In this study of 273 patients who underwent unilateral primary THA due to hip OA, 132 355 patients (improvement rate 48.4%) demonstrated improvement in their total CDL stage 356 three months after THA. Additionally, 15 out of 25 in the GLFS-25 showed 357 improvements in over 60% of the patients. Based on these results, approximately half of 358 the patients showed improvement in LS three months after THA. These findings 359 underscore the significant impact of THA on improving LS, particularly in improving 360 locomotion movements. The results emphasize the pivotal role of postoperative 361 rehabilitation, suggesting the need to set target rehabilitation goals for enhancing motor 362 function after THA in hip OA patients.

363

# 364 Acknowledgments

365 The authors would like to thank Masaru Ochiai, Tsubasa Kawaguchi, Aya Unoki,

366 Wakaba Iha, Akari Nagatomo, Kensuke Okamura and Mami Kanno for their assistance

- 367 in recruiting the participants and for useful advice.
- 368

# 369 Funding

370 This work was supported by the Japan Society for the Promotion of Science Grants-in-

371 Aid for Scientific Research (Grant No. 24K20438). The funders had no role in study

design, data collection and analysis, decision to publish, or preparation of the manuscript.

373 There was no additional external funding received for this study.

374

## 375 **References**

- World Health Organization, Health topics: Ageing. <u>https://www.who.int/health-</u>
   topics/ageing#tab=tab 1. Accessed 10 Sept 2023.
- Mitani G, Nakamura Y, Miura T, Harada Y, Sato M, Watanabe M. Evaluation of the
   association between locomotive syndrome and metabolic syndrome. J Orthop Sci.
   2018;23:1056-62. doi: 10.1016/j.jos.2018.07.004.
- 381 3. Nakamura K. Locomotive syndrome: disability-free life expectancy and locomotive
  382 organ health in a "super-aged" society. J Orthop Sci. 2009;14:1-2. doi:
  383 10.1007/s00776-008-1302-y.
- Ishibashi H. Locomotive syndrome in Japan. Osteoporos Sarcopenia. 2018;4:86-94.
   doi: 10.1016/j.afos.2018.09.004.
- 386 5. Nakamura K. A "super-aged" society and the "locomotive syndrome". J Orthop Sci.

387 2008;13:1-2. doi: 10.1007/s00776-007-1202-6.

- Nakamura K, Ogata T. Locomotive syndrome: definition and management. Clin Rev
   Bone Miner Metabol. 2016;14:56-67. doi: 10.1007/s12018-016-9208-2.
- 390 7. Ogata T, Muranaga S, Ishibashi H, Ohe T, Izumida R, Yoshimura N et al.
- 391 Development of a screening program to assess motor function in the adult population:
  a cross-sectional observational study. J Orthop Sci. 2015;20:888-95. doi:
  10.1007/s00776-015-0737-1.
- Yoshimura N, Muraki S, Oka H, Tanaka S, Ogata T, Kawaguchi H et al. Association
   between new indices in the locomotive syndrome risk test and decline in mobility:
   third survey of the ROAD study. J Orthop Sci. 2015;20:896-905. doi:
   10.1007/s00776-015-0741-5.
- Miyazaki S, Tsuruta K, Yoshinaga S, Yamaguchi Y, Fujii Y, Arakawa H et al. Effect
   of total hip arthroplasty on improving locomotive syndrome in hip disease patients:
   A prospective cohort study focused on total clinical decision limits stage 3. J Orthop
   Sci. 2022;27:408-13. doi: 10.1016/j.jos.2020.12.028.
- 402 10. Miyazaki S, Yoshinaga S, Tsuruta K, Hombu A, Fujii Y, Arakawa H et al. Total
  403 Knee Arthroplasty Improved Locomotive Syndrome in Knee Osteoarthritis Patients:
  404 A Prospective Cohort Study Focused on Total Clinical Decision Limits Stage 3.
  405 Biomed Res Int. 2021:3919989. doi: 10.1155/2021/3919989.
- 406 11. Bahl JS, Nelson MJ, Taylor M, Solomon LB, Arnold JB, Thewlis D. Biomechanical
  407 changes and recovery of gait function after total hip arthroplasty for osteoarthritis: a
  408 systematic review and meta-analysis. Osteoarthritis Cartilage. 2018;26:847-63. doi:

409 10.1016/j.joca.2018.02.897.

410	12. Huch K, Müller KA, Stürmer T, Brenner H, Puhl W, Günther KP. Sports activities 5
411	years after total knee or hip arthroplasty: the Ulm Osteoarthritis Study. Ann Rheum
412	Dis. 2005;64:1715-20. doi: 10.1136/ard.2004.033266.
413	13. Ries MD, Philbin EF, Groff GD, Sheesley KA, Richman JA, Lynch F Jr. Effect of
414	total hip arthroplasty on cardiovascular fitness. J Arthroplasty. 1997;12:84-90. doi:
415	10.1016/s0883-5403(97)90052-8.
416	14. Larsen K, Sørensen OG, Hansen TB, Thomsen PB, Søballe K. Accelerated
417	perioperative care and rehabilitation intervention for hip and knee replacement is
418	effective: a randomized clinical trial involving 87 patients with 3 months of follow-
419	up. Acta Orthop. 2008;79:149-59. doi: 10.1080/17453670710014923.


- 420 15. Seichi A, Hoshino Y, Doi T, Akai M, Tobimatsu Y, Iwaya T. Development of a
  421 screening tool for risk of locomotive syndrome in the elderly: the 25-question
  422 Geriatric Locomotive Function Scale. J Orthop Sci. 2012;17:163-72. doi:
  423 10.1007/s00776-011-0193-5.
- 424 16. Akai M, Doi T, Seichi A, Okuma Y, Ogata T, Iwaya T. Locomotive Syndrome:
  425 Operational Definition Based on a Questionnaire, and Exercise Interventions on
  426 Mobility Dysfunction in Elderly People. Clin Rev Bone Miner Metab. 2016;14:119427 30. doi: 10.1007/s12018-016-9210-8.
- 428 17. Maezawa K, Nozawa M, Yuasa T, Sato H, Gomi M, Kaneko K. Early clinical results
  429 of total hip arthroplasty assessed with the 25-question Geriatric Locomotive Function
  430 Scale and muscle strength testing. J Orthop Sci. 2018;23:538-41. doi:

### 431 10.1016/j.jos.2018.02.012.

432	18.	McLaughlin JR, Lee KR. Total hip arthroplasty with an uncemented tapered femoral
433		component in patients younger than 50 years of age: a minimum 20-year follow-up
434		study. J Arthroplasty. 2016;31:1275-8. doi: 10.1016/j.arth.2015.12.026.
435	19.	Ateschrang A, Weise K, Weller S, Stöckle U, de Zwart P, Ochs BG. Long-term
436		results using the straight tapered femoral cementless hip stem in total hip
437		arthroplasty: a minimum of twenty-year follow-up. J Arthroplasty. 2014;29:1559-65.
438		doi: 10.1016/j.arth.2014.02.015.
439	20.	Ohmori T, Kabata T, Kato S, Takagi T, Kajino Y, Inoue D et al. The efficacy of total
440		hip arthroplasty on locomotive syndrome and its related physical function in patients
441		with hip osteoarthritis. J Orthop Sci. 2021;26:389-95. doi: 10.1016/j.jos.2020.04.011.
442	21.	Taniguchi N, Jinno T, Endo H, Wako M, Tatsuno R, Ochiai S et al. Improvement of
443		locomotive syndrome after total hip arthroplasty: A two-year longitudinal cohort
444		study. Mod Rheumatol. 2021;31:1050-8. doi: 10.1080/14397595.2020.1823552.
445		

# 446 Supporting information

- 447 S1 File. Raw data
- 448 S2 File. Codebook
- 449 S3 File. STROBE Statement






Figure 2